Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
Abstract
Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required.
| Authors | Raninga, Prahlad; Lee, Andy; Sinha, Debottam; Dong, Lan-feng; Datta, Keshava; Lu, Xue; Kalita-de Croft, Priyakshi; Dutt, Mriga; Hill, Michelle M.; Pouliot, Normand M.; Gowda, Harsha; Kalimutho, Murugan; Neuzil, Jiri; Khanna, Kum Kum |
|---|---|
| Journal | THERANOSTICS |
| Pages | 5259-5275 |
| Volume | 10 |
| Date | 1/01/2020 |
| Grant ID | |
| Funding Body | Cure Cancer Australia |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.7150/thno.42705 |
| Download Article |